Patient description: A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow: A wellbeing, well-nourished man, non-icteric, cooperative and alert Weight: 73 kg Height: 177 BP: 120/80 HR: 90/min RR: 22/min Hgb: 13 g/dl WBC: 8000 /mm3 (Neutrophil: 2700/mm3) Plt: 300000 /ml AST: 40 U/L ALT: 56 U/L Alk P: 147 U/L Bill total: 1.2 mg/dl ESR: 120 mm/hr MPO-ANCA: 153 EU

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Relapsed/Refractory Non-Hodgkin's Lymphoma Non-Hodgkin's lymphoma (NHL) confirmed by histopathology, preferably in the detection of tumor tissue PD-L1 expression. 2. A recurrent or refractory disease defined as: 1) recurrence of disease after complete remission (CR); or 2) partial remission (PR), disease stabilization (SD), or disease Progress (PD) when the treatment is completed prior to enrollment in the study. 3. Age≥18 years old, both men and women. 4. The ECOG score is 0-2. 5. There is at least one evaluable lesion (maximum diameter>15mm or shortest diameter>10mm). Preferably, PET-CT shows high metabolism of FDG. 6. Have received appropriate first-line and more-line treatment of the corresponding NHL. 7. Liver and kidney function: blood bilirubin≤35μmol/L, AST or ALT is less than 2 times the upper limit of normal value, serum creatinine≤150μmol/L. 8. The thyroid function is normal. 9. Women of childbearing age are required to undergo a pregnancy test before receiving treatment and must agree to take effective contraception during treatment. 10. Subjects must sign an informed consent form  Age<18 years old； 2. Received ASCT within 90 days prior to the first use of the study drug; 3. Severe allergies, or patients known to be allergic or intolerant of the drug components of the chemotherapy regimen; 4. Active, unrecognized or suspected autoimmune disease, or a history of autoimmune disease within 2 years; 5. Previously exposed to any antibody against PD-1, PD-L1 or cytotoxic T lymphocyte-associated antigen 4 6. Exposure to any study drug within 4 weeks prior to the first use of the study drug 7. Expose to the last radiotherapy or anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy or arterial embolization) within 3 weeks prior to the first use of the study drug. 8. Have a history of oncology and have received any treatment for this tumor in the past 3 years; 9. Patients during pregnancy and lactation; 10. Accompanied by severe heart disease, including acute myocardial infarction within 6 months, or in accordance with New York Heart Association cardiac function III or IV; 11. A serological test for HIV or active hepatitis C virus is known to be positive; 12. Hepatitis B virus carriers or hepatitis B virus DNA positive untreated patients are known; 13. TB patients active period 14. Other circumstances that the investigator believes are not suitable for inclusion